Skip to content

Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia

Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia: a Prospective, Non-interventional, Multi-centric, Clinical Performance Study

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05613322
Acronym
PHENOTECH-1
Enrollment
246
Registered
2022-11-14
Start date
2023-01-18
Completion date
2024-09-05
Last updated
2024-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteremia Sepsis

Keywords

Antibiotic, Susceptibility, AST, E.coli, K. pneumoniae, Phenotech

Brief summary

The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K. pneumoniae) to clinically relevant antibiotics. The study is designed as a prospective, non-interventional, multi-center, single-arm study. The blood culture samples from bacteremia patients that are positive for E. coli or K. pneumoniae will be tested with the Resistell Phenotech device after strain identification by MALDI-TOF. The results of the Resistell AST will be compared with the results from the disk diffusion tests (all sites use the Kirby-Bauer disk diffusion test), and site dependent tests (VITEK® 2, BD Phoenix™, MicroScan WalkAway system, and/or EUCAST RAST), which are currently the standard AST methods in the microbiology laboratories at the participating sites.

Interventions

DIAGNOSTIC_TESTResistell Phenotech

Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.

Sponsors

Resistell AG
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who have signed a General Consent form approving use of their residual blood samples for research purposes (applicable at CHUV only) * Patients who have signed a consent allowing the use of their residual sample (Restprobenerklärung) (applicable at MUI, only) * Patients over the age of 18 years (\>18) * Patients with bacteremia considered to be due to E. coli or K. pneumoniae * Patients whose positive blood cultures were not older than 24 hours at the time of AST start

Exclusion criteria

* Patients with documented refusal of the use of biological material for research purposes (applicable at CHUV, only) * Patients with polymicrobial bacteremia

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of the Resistell Phenotech vs Kirby-Bauer18 monthsTo assess the sensitivity of the Resistell Phenotech in detecting antibiotic susceptible bacteria in blood samples positive for E. coli or K. pneumoniae, compared to the gold standard Kirby-Bauer disk diffusion test.

Secondary

MeasureTime frameDescription
Specificity and accuracy of the Resistell Phenotech vs Kirby-Bauer18 monthsTo assess the specificity and accuracy of the Resistell Phenotech in detecting antibiotic susceptible bacteria in blood samples positive for E. coli or K. pneumoniae, compared to the gold standard Kirby-Bauer disk diffusion test.
Sensitivity, specificity, and accuracy of the Resistell Phenotech vs other comparators18 monthsTo assess the sensitivity, specificity, and accuracy of the Resistell Phenotech in detecting antibiotic susceptible bacteria in blood samples positive for E. coli or K. pneumoniae, compared to other routine diagnostic AST tests run at each site
Time to result of Resistell Phenotech vs Kirby-Bauer and other comparators18 monthsTo assess the difference between time to result (TTR) of Resistell Phenotech and the TTR of the Kirby-Bauer and the other routine diagnostic AST methods run at each site.
Category agreement and discrepancies18 monthsTo assess category agreement (CA), very major discrepancy (VMD), major discrepancy (MD) of the results obtained with Resistell Phenotech compared to the Kirby-Bauer and the other routine diagnostic AST test results at each site

Countries

Austria, Spain, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026